who owns the patent for semaglutide Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. π Demand GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Semaglutide Composition-of-Matter Patent Lifecycle |
Pay in 4 interest-free payments of $5.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Jul 31 - Aug 5


























